Blood protein may hold key to depression treatment success
NCT ID NCT02051413
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study looked at whether certain proteins called beta-arrestins can predict how well people with major depression respond to the antidepressant venlafaxine (Effexor). Researchers followed 67 patients for three months, measuring their depression symptoms and checking blood samples for these proteins. The goal was to find a simple biological marker that could help doctors choose the right treatment from the start.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
venlafaxine (extended release)
What this could lead to
If successful, this could help doctors predict which patients will benefit from venlafaxine, making depression treatment more personalized.
What could go wrong
This is a small, early-stage study (67 participants) looking at biological markers, not a treatment itself. The findings may not lead to a practical test or apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE EPISODE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU de Bicetre
Le Kremlin-Bicêtre, 94275, France